Trader consensus on Polymarket reflects an 82.5% implied probability for no new WHO-designated COVID-19 variant of concern before 2027, driven by sustained global immunity from widespread vaccination and prior infections, alongside effective updated vaccines targeting Omicron sublineages. Recent monitoring of highly mutated strains like BA.3.2 ("Cicada"), which emerged in early 2026 but remains classified only as a Variant Under Monitoring (VUM) rather than escalating to VOC status, underscores the high bar for new designations—no such upgrades have occurred since Omicron in 2021. As of mid-May 2026, circulating variants such as XFY, PQ.17, and XFZ show no evidence of increased severity or immune escape warranting concern, with ongoing genomic surveillance by WHO and ECDC providing reassurance amid low-to-moderate case activity.